Signaling angiogenesis and lymphangiogenesis

Current Opinion in Cell Biology

Volumn 10, Issue 2, 1998, Pages 159-164

  Korpelainen, Eija I ^a   Alitalo, Kari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD VESSEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; TUMOR GROWTH;

EID: 0032053767     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(98)80137-3     Document Type: Article

References (59)

1. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol. 11:1995;73-91.
2. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
3. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. of special interest Science. 275:1997;964-967 A contribution that could mean that circulating endothelial precursor cells contribute to angiogenic processes. If confirmed, this could be important for specific gene targeting to endothelial cells involved in neovascularization.
4. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endoctrine Rev. 18:1997;4-25.
5. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. of special interest Proc Natl Acad Sci USA. 94:1997;8761-8766 A demonstration that withdrawal of enforced VEGF expression leads to apoptosis of newly formed tumor vessels.
6. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1:1995;1024-1028.
7. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hilan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. of outstanding interest Nature. 380:1996;438-442 Striking heterozygotic lethality of VEGF knockout mice suggests that VEGF regulates embryonic vessel development in a tightly dose-dependent manner.
8. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoek A, Harpal K, Ebenhardt C, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. of outstanding interest Nature. 380:1996;435-439 See annotation to Ferrara, 1996 [7].
9. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376:1995;66-70.
10. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:1995;62-66.
11. Eichmann A, Corbel C, Nataf V, Vaigot P, Breant C, Le Douarin NM. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. of special interest Proc Natl Acad Sci USA. 94:1997;5141-5146 Suggests that VEGFR-2-positive cells contain hemangioblasts able to give rise to both endothelial and hemopoietic lineages.
12. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
13. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 16:1996;4604-4613.
14. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature. 386:1997;403-407.
15. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. of special interest Proc Natl Acad Sci USA. 93:1996;10595-10599 A demonstration that inactivation of the VHL tumor suppressor gene leads to abnormal stabilization of VEGF mRNA.
16. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, Linehan WM. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. of special interest Proc Natl Acad Sci USA. 93:1996;10589-10594 See annotation to Iliopoulos, 1996 [15].
17. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA. 88:1991;9267-9271.
18. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placental growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 269:1994;25646-25654.
19. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (PIGF-2) is expressed in human umbilical vein endothelial cells and placenta. Growth Factors. 9:1993;259-268.
20. Olofsson B, Pajusola K, Kaipainen A, Von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. of special interest Proc Natl Acad Sci USA. 93:1996;2576-2581 A novel member of the VEGF family.
21. Grimmond S, Lagercrantz J, Drinkwater C, Silins G, Townson S, Pollock P, Gotley D, Carson E, Rakar S, Nordenskjold M, et al. Cloning and characterisation of a novel human gene related to vascular endothelial growth factor. of special interest Genome Res. 6:1996;124-131 See annotation to Olofsson, 1996 [20].
22. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. of special interest EMBO J. 15:1996;290-298 See annotation Olofsson, 1996 [20].
23. Lee J, Gray A, Yuan J, Louth S-M, Avraham H, Wood W. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. of special interest Proc Natl Acad Sci USA. 93:1996;1988-1992 See annotation to Olofsson, 1996 [20].
24. Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. of special interest Proc Natl Acad Sci USA. 93:1996;11675-11680 See annotation to Olofsson, 1996 [20].
25. Yamada Y, Nezu J, Shimane M, Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. of special interest Genomics. 42:1997;483-488 See annotation to Olofsson, 1996 [20].
26. Olofsson B, Pajusola K, von Euler G, Chilov D, Alitalo K, Eriksson U. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. of special interest J Biol Chem. 271:1996;19310-19317 Alternative splicing produces two isoforms of VEGF-B of different bioavailability.
27. Cao Y, Chen H, Zhou L, Chiang M-K, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, Tsang ML-S. Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem. 271:1996;3154-3162.
28. Kaipainen A, Korhonen J, Mustonen T, van Hinsberg VM, Fang G-H, Dumont D, Breitman M, Alitalo K. Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to endothelium of lymphatic vessels during development. Proc Natl Acad Sci USA. 92:1995;3566-3570.
29. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. of outstanding interest EMBO J. 16:1997;3898-3911 Receptor specificity (and therefore possibly the biological role) of VEGF-C is shown to be regulated by protolytic processing.
30. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. of outstanding interest Science. 276:1997;1423-1425 The strongest evidence yet for the first lymphangiogenic factor.
31. Oh SJ, Jeltsch MM, Birkenhager R, McCarthy JE, Weich HA, Christ B, Alitalo K, Wilting J. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol. 188:1997;96-109.
32. Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J, Kivinen L, Laiho M, Olofsson B, Joukov V, et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene. 14:1997;2475-2483.
33. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14:1995;5884-5891.
34. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 376:1995;70-74.
35. Partanen J, Puri MC, Schwartz L, Fischer K-D, Bernstein A, Rossant J. Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. of special interest Development. 122:1996;3013-3021 A detailed chimeric analysis of Tie function in the embryonic and adult vasculature.
36. Dumont DJ, Gradwohl G, Fong G-H, Puri MC, Gertsenstein M, Auerbach A, Breitman ML. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8:1994;1897-1909.
37. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Raziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. of special interest Cell. 87:1997;1161-1169 Cloning of the long-sought ligand for Tie-2.
38. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. Anglopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. of outstanding interest Science. 277:1997;55-60 An interesting novel concept of an inhibitory ligand for an endothelial receptor tyrosine kinase.
39. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. of special interest Cell. 87:1997;1161-1169 Determination of the physiological role of Ang-1.
40. Vikkula M, Boon LM, Carraway KL, Cavert JT, Diamonti JA, Goumnerov B, Pasy KA, Marchuk DA, Warman ML, Cantley LC, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. of special interest Cell. 87:1996;1181-1190 A hereditary venous malformation is shown to segregate with an activating mutation in the Tie-2 locus.
41. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, et al. Role of tissue factor in embryonic blood vessel development. Nature. 383:1996;73-75.
42. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. of special interest Science. 277:1997;242-245 Identification of deficient pericyte development as the underlying cause of hemorrhage in PDGF-5 knockout mice.
43. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development. 121:1995;1845-1854.
44. Oshima M, Oshima H, Taketo MM. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol. 179:1996;297-302.
45. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 8:1994;345-351.
46. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 13:1996;189-195.
47. Folkman J, D'Amore P. Blood vessel formation: what is its molecular basis? Cell. 87:1996;1153-1155.
48. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature. 362:1993;841-844.
49. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 92:1995;10457-10461.
50. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56:1996;3540-3545.
51. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-960.
52. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
53. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. of outstanding interest Cell. 88:1997;277-285 Identification of a second endogenous angiogenesis inhibitor with potential for dormancy therapy.
54. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. of outstanding interest Nat Med. 2:1996;689-692 A striking new phenomenon which could have a key role in human cancer.
55. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
56. 3 can regulate matrix degradation via matrix metalloprotease 2.
57. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. of outstanding interest Science. 275:1997;547-550 The first encouraging evidence that tumor vessels can be targeted. Furthermore, intravascular coagulation seemed to be more effective than toxins.
58. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA. 94:1997;7192-7197.
59. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGFR receptor 3 (Flt4). Proc Natl Acad Sci USA. 95:1998;548-553.